fbpx

News

Lundbeckfonden Ventures News

Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that it has filed an action in federal district court for the District of Columbia against the Food and Drug Administration, seeking an order requiring FDA to grant final approval to Envarsus® XR.
Trial using Nexstim's Navigated Brain Therapy (NBT®) system for pain relief in patients suffering from chronicneuropathic painSecond study using Nexstim's technology at The Walton Centre, the only specialist neuroscience centre in the NHS, to show long term effect of NBT®Previous study demonstrated 44% of patients obtained clinically meaningful pain relief of at least 3 weeks'...
BONESUPPORT and Orthocell agreement to facilitate:Partnership to co-develop bone repair products utilizing the unique eluting bone remodelling capabilities of CERAMENTT and the important collagen properties of CelgroTOrthocell and BONESUPPORT to co-develop CelgroT collagen scaffold to create next generation bone repair product that also induces bone growth
CANTERBURY, UK, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Ziarco Group Ltd., a biopharmaceutical company focusing on inflammatory skin diseases, today announced the addition of Mike Grey to its Board of Directors as an independent director. Mr. Grey is Chairman and Chief Executive Officer (CEO) of Reneo Pharmaceuticals, a privately held biotechnology company, and a Venture...
LEXINGTON, Mass., December 2, 2014 /PRNewswire/ -- scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that Leonard D. Schaeffer has been appointed to scPharmaceutical's board of directors.
Collaboration to generate novel diagnostic products to support personalized therapies for microbiome-related diseases
SAN DIEGO, Nov. 14, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer of Celladon, was selected to present three-year long-term follow up data of MYDICAR in patients with advanced heart failure during the...
SAN DIEGO, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced financial results for the quarter ended September 30, 2014 and recent corporate highlights and updates.
Proceeds to enable clinical Phase 2 Proof-of-Concept studies for two lead compounds - a histamine H4 receptor antagonist for atopic dermatitis and a topical cPLA2 inhibitor for psoriasis
1 41 42 43 44 45 62

Lundbeckfonden Ventures

Nyheder

Acacia Pharma Group PLC – Issue of Equity on Share Subscription and Licensing agreement With Cosmo Pharmaceuticals
13. January 2020
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense
13. January 2020
Christine Soden to step down and Gary G. Gemignani to be appointed as new CFO
13. January 2020